These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18034197)

  • 1. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.
    Cheong SC; Wang Y; Meng JH; Hill R; Sweeney K; Kirn D; Lemoine NR; Halldén G
    Cancer Gene Ther; 2008 Jan; 15(1):40-50. PubMed ID: 18034197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
    Oberg D; Yanover E; Adam V; Sweeney K; Costas C; Lemoine NR; Halldén G
    Clin Cancer Res; 2010 Jan; 16(2):541-53. PubMed ID: 20068104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
    Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
    J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT1 interaction with E3-14.7K in monocytes affects the efficacy of oncolytic adenovirus.
    Spurrell E; Gangeswaran R; Wang P; Cao F; Gao D; Feng B; Wold W; Tollefson A; Lemoine NR; Wang Y
    J Virol; 2014 Feb; 88(4):2291-300. PubMed ID: 24335311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
    Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
    Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.
    Wong HH; Jiang G; Gangeswaran R; Wang P; Wang J; Yuan M; Wang H; Bhakta V; Müller H; Lemoine NR; Wang Y
    Mol Ther; 2012 Feb; 20(2):306-16. PubMed ID: 22086234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
    Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
    Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
    Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
    Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
    Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
    Wang Y; Hallden G; Hill R; Anand A; Liu TC; Francis J; Brooks G; Lemoine N; Kirn D
    Nat Biotechnol; 2003 Nov; 21(11):1328-35. PubMed ID: 14555956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.
    Bauerschmitz GJ; Guse K; Kanerva A; Menzel A; Herrmann I; Desmond RA; Yamamoto M; Nettelbeck DM; Hakkarainen T; Dall P; Curiel DT; Hemminki A
    Mol Ther; 2006 Aug; 14(2):164-74. PubMed ID: 16580264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells.
    Hibma MH; Real NC; Wiles A; Dobson-Le D; Dix BR; Wynford-Thomas D; Braithwaite AW; Royds JA
    Virus Res; 2009 Oct; 145(1):112-20. PubMed ID: 19576936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
    Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
    Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells.
    Li Y; Li YF; Si CZ; Zhu YH; Jin Y; Zhu TT; Liu MY; Liu GY
    Virus Res; 2016 Jul; 220():172-8. PubMed ID: 27157859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.